2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Targeted Therapy and Renal Cell Carcinoma: Are We Making Progress?
Robert J. Amato, DO, Weill Medical College of Cornell University, University of Texas Health Science Center - Houston, The Methodist Hospital Research Institute, Houston, Texas

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Current Topics

Risk Factors for Sutent® Toxicity in Renal Cell Cancer Defined (7/23/2008)
Researchers from the Netherlands have reported that severe toxicity following treatment of advanced renal cell carcinoma (RCC) with Sutent® (sunitinib) is related to low body surface, high age, and female gender. The details of this study appeared in the July 15, 2008 issue of the British Journal of Cancer.

Thalomid® and Revlimid® Active as Primary Treatment for Metastatic Renal Cell Carcinoma (7/1/2008)
Researchers from Methodist Hospital in Houston, Texas, have reported that both Revlimid® (lenalidomide) and Thalomid® (thalidomide) have significant activity in newly diagnosed patients with metastatic renal cell carcinoma (MRCC). The details of these two studies were published in the June 2008 issue of the American Journal of Clinical Oncology.

Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Renal Cell Cancer (6/4/2008)
According to updated results from a Phase III clinical trial, initial treatment of metastatic renal cell cancer (RCC) with Sutent® (sunitinib) results in significantly better response rates and progression-free survival than treatment with interferon alfa. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).

Conventional Chemotherapy Outperforms Xeloda® in Older Breast Cancer Patients (6/4/2008)
Among women aged 65 or older with operable breast cancer, risk of recurrence and risk of death were higher among those treated with Xeloda® (capecitabine) monotherapy than among those treated with AC or CMF chemotherapy. These were the results of the CALGB/CTSU 49907 trial, presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).

Avastin® and Interferon Superior to Interferon Alone for Metastatic Renal Cell Carcinoma (5/15/2008)
Researchers affiliated with CALGB 90206 have reported that the addition of Avastin® (bevacizumab) to interferon improves overall and progression-free survival in patients with metastatic renal cell carcinoma. The details of this study were presented at the 2008 Genitourinary Cancers Symposium in San Francisco in February.